Research & Development
Policy & Regulation
Trends & Finance
FYR, Medicover partner to expand into North America
The collaboration will support pharmaceutical companies with clinical trial assay development and implementation, codevelopment of novel diagnostic technologies, and companion diagnostic testing services.
August 30, 2022
NanoDx, SkyWater launch nano biosensor
The companies said that as a result of the development, NanoDx is ready to prepare and submit the product for review by the U.S. Food and Drug Administration (FDA) with the aim of eventually commercializing a product based on the technology.
August 25, 2022
PathAI and Bristol Myers Squibb extend AI partnership
"We will build on our work using AI-based pathology in translational research and validate the use of this technology through clinical trials and diagnostic development," Andy Beck, cofounder and CEO of PathAI, said in a statement.
August 24, 2022
Satio partners with nonprofit institute in Senegal
Under the deal, the company's SatioRx intradermal patches will be combined with Institut Pasteur de Dakar technologies to drive clinical development and access to vaccine patches. The partnership will also encompass diagnostic patches for blood sampling, genetic testing, and pathogen surveillance, Satio said.
August 22, 2022
FYR Dx, Medicover partner on assay, tech development
The firms plan to support pharmaceutical companies with clinical trial assay development and implementation, codevelopment of novel diagnostic technologies, and companion diagnostic testing services.
August 16, 2022
Nucleai, Ultivue to partner on AI-based drug development platform
Under a comarketing agreement, the firms will integrate Nucleai's AI spatial models with Ultivue's imaging technology with the aim of speeding drug development.
June 5, 2022
DNA forensic evidence frees Ohio man of rape, attempted rape
‘Good’ cholesterol worse for some adults: NIH study
Empatica receives FDA clearance for digital biomarker platform, closes Series B financing
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
Week in Review: Elizabeth Holmes sentenced; good cholesterol worse for some adults; earlier type 2 diabetes diagnosis; and more
Chembio Diagnostics applies for FDA CLIA waiver for HIV, syphilis test
Hitachi High-Tech partners, invests in Invivoscribe
The partnership brings together Invivoscribe's technology, assay and bioinformatics development, global clinical testing, and international regulatory knowledge and Hitachi High-Tech's experience in measurement and analysis systems technologies.
May 9, 2022
New task force promotes pathology for cancer research
Efforts of the task force include an award program for outstanding pathology research in cancer, knowledge hubs on pathology for medical students, and the development and adoption of new technologies in pathology. Parwani shed light on the new task force in an interview with LabPulse at the recent American Association for Cancer Research (AACR) meeting in New Orleans.
May 2, 2022
Huron Digital taps Audil Virk as president
Virk has executive leadership and operational experience in general management, strategy, product development, and technology commercialization, Huron said.
April 14, 2022
MilliporeSigma closes Exelead buy for lipid nanoparticle boost
MilliporeSigma plans to invest more than $565 million over the next 10 years to further expand Exelead's PEGylated research and development and its LNP-based drug delivery technology, which is key to mRNA vaccines and therapeutics, MilliporeSigma said.
February 22, 2022
SLAS 2022: Diagnostics tech should be based on clinical need
Traditionally, scientists and engineers create a technology, find a biological application for it, and publish it in a big academic journal. For companies, the cycle is a bit different: a company creates a technology, most likely for life sciences research, and then years (if not decades) later, someone discovers a clinical application for it.
February 9, 2022
DiaCarta, NCI to work on cancer detection technology
Under a two-year Cooperative Research and Development Agreement (CRADA), the organizations will work on investigating low-frequency mutation events in cancers and rare diseases using DiaCarta's technology, as well as develop xenonucleic acid probes for in situ cancer cell detection.
January 6, 2022
Page 1 of 3